EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	220	544/396	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/06/21 14:45
L3	26	l2 and cetirizine	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/06/21 14:45
L4	1059	514/255.05	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/06/21 14:45
L5	29	l4 and cetirizine	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/06/21 14:45

10729856

FILE 'HOME' ENTERED AT 14:49:32 ON 21 JUN 2007

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:49:40 ON 21 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2007 HIGHEST RN 938114-25-1
DICTIONARY FILE UPDATES: 20 JUN 2007 HIGHEST RN 938114-25-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10729856.str



chain nodes :

Karen Cheng

10729856

7 8 9 10 11 12 13 14 27 28 29 30 31 32 33 34 35 36 37 38 39 40
41 42 43
ring nodes :
1 2 3 4 5 6 15 16 17 18 19 20 21 22 23 24 25 26
chain bonds :
1-14 2-29 2-30 3-31 3-32 4-7 5-35 5-36 6-33 6-34 7-8 7-37 7-38 8-9
8-39 8-40 9-10 10-11 10-41 10-42 11-12 11-13 13-43 14-15 14-21 14-28
18-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20 21-22
21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
1-2 1-6 1-14 2-3 3-4 4-5 4-7 5-6 8-9 9-10
exact bonds :
2-29 2-30 3-31 3-32 5-35 5-36 6-33 6-34 7-8 7-37 7-38 8-39 8-40 10-11
10-41 10-42 13-43 14-15 14-21 14-28 18-27
normalized bonds :
11-12 11-13 15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24
24-25 25-26
isolated ring systems :
containing 1 : 15 : 21 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS
36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR

Karen Cheng



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 full
FULL SEARCH INITIATED 14:50:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      397 TO ITERATE

100.0% PROCESSED      397 ITERATIONS                          27 ANSWERS
SEARCH TIME: 00.00.01

L2            27 SEA SSS FUL L1

=> s l2 and dihydrochloride
        122896 DIHYDROCHLORIDE
            20 DIHYDROCHLORIDES
        122896 DIHYDROCHLORIDE
                  (DIHYDROCHLORIDE OR DIHYDROCHLORIDES)
L3            8 L2 AND DIHYDROCHLORIDE

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                              177.50     177.71

FILE 'CAPLUS' ENTERED AT 14:50:45 ON 21 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

Karen Cheng

10729856

FILE COVERS 1907 - 21 Jun 2007 VOL 146 ISS 26
FILE LAST UPDATED: 20 Jun 2007 (20070620/ED)


```
=> s l3
L4          250 L3

=> s l4 and polymorph
           8022 POLYMORPH
           9079 POLYMORPHS
          13936 POLYMORPH
                  (POLYMORPH OR POLYMORPHS)
L5            0 L4 AND POLYMORPH

=> s l4 and crystalline
          78232 CRYSTALLINE
            249 CRYSTALLINES
          78460 CRYSTALLINE
                  (CRYSTALLINE OR CRYSTALLINES)
         357907 CRYST
           1801 CRYSTS
         359175 CRYST
                  (CRYST OR CRYSTS)
         384544 CRYSTALLINE
                  (CRYSTALLINE OR CRYST)
L6            7 L4 AND CRYSTALLINE

=> d ibib abs hitstr tot
```

Karen Cheng

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:433986 CAPLUS
DOCUMENT NUMBER: 146:428753
TITLE: Mannitol for preparing compositions for oral administration
INVENTOR(S): Makino, Tadashi; Fukami, Jinichi
PATENT ASSIGNEE(S): Kyoto Pharmaceutical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 39pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007043538	A1	20070419	WO 2006-JP320235	20061004

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-292922 A 20051005
AB Disclosed are: a composition for oral administration which enables the production of an molded product for oral administration (e.g., a preparation having both rapid disintegrating property and high hardness) at low cost by using a general-purpose apparatus; a molded product for oral administration which is an application example of the composition; and a method for production of the composition. The composition can be produced by a process comprising the steps of: treating a granulation composition comprising a δ-type D-mannitol crystal and a disintegrating agent (e.g., crospovidone) with a water-soluble solvent to convert at least a part of the δ-type D-mannitol crystal into a β-type D-mannitol crystal; and drying the granulation composition to inhibit the growth of the β-type D-mannitol crystal produced by the conversion.
IT 83881-52-1, Cetirizine hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of oral prepns. containing δ-mannitol and disintegrators)
RN 83881-52-1 CAPLUS
CN Acetic acid, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1329533 CAPLUS
DOCUMENT NUMBER: 146:87555
TITLE: Cetirizine hydrochloride masticatory tablet and its preparation
INVENTOR(S): Gu, Xuchu; Zhong, Xuebin
PATENT ASSIGNEE(S): Nanjing Golden Eagle Medicinery Technology Development Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 6pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1875970	A	20061213	CN 2005-10040439	20050608

PRIORITY APPLN. INFO.: CN 2005-10040439 20050608
AB The title masticatory tablet is composed of cetirizine hydrochloride 1, crystalline cellulose 10-50, sucrose 10-50, β-cyclodextrin 1-10, sodium carboxymethyl starch 1-10, sodium saccharin 0.2-5, magnesium stearate 0.1-10, micropowder silica gel 0.1-5 part, and water proper quantity. The preparation method comprises pulverizing, sieving by 80 mesh sieve, mixing cetirizine hydrochloride, sodium saccharin, β-cyclodextrin, sucrose powder, and crystalline cellulose with distilled water to obtain soft material, sieving by 40 mesh sieve, prilling, drying at 60° for 2 h, sieving by 30 mesh sieve, adding sodium carboxymethyl starch, magnesium stearate, and micropowder silica gel, stirring, and pressing. The invention can be used for treating seasonal or perennial allergic rhinitis, and urticaria and cutaneous pruritus caused by allergen.
IT 83881-52-1, Cetirizine hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cetirizine hydrochloride masticatory tablet and its preparation)
RN 83881-52-1 CAPLUS
CN Acetic acid, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:78236 CAPLUS
DOCUMENT NUMBER: 142:162672
TITLE: Crystalline cetirizine monohydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Rao, Uppala Venkata Bhaskara; Reddy, Konda Srinivasa
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020608	A1	20050127	US 2004-809192	20040325
IN 2003MA00252	A	20050304	IN 2003-MA252	20030325

PRIORITY APPLN. INFO.: IN 2003-MA252 A 20030325
AB A novel crystalline form of cetirizine monohydrochloride and processes for making the crystalline form as well as compns., pharmaceutical compns., and methods utilizing the crystalline form are described. A process for preparation of a crystalline form of cetirizine monohydrochloride, comprises (1) providing a solid residue of crude cetirizine monohydrochloride; (2) contacting the crude residue with a ketone solvent to cause separation of a solid mass; and (3) isolating the solid mass thereby obtaining the crystalline form of cetirizine monohydrochloride. Tablets for the treatment of allergic syndromes were formulated containing crystalline cetirizine monohydrochloride 10, CaCO3 500, PVP 17, Avicel 15, mannitol 400, maltodextrin 15, aspartame 3, and aroma 20 mg each.
IT 83881-52-1P, Cetirizine dihydrochloride
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
RN 83881-52-1 CAPLUS
CN Acetic acid, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:2182 CAPLUS
DOCUMENT NUMBER: 142:93859
TITLE: Process for the preparation of an amorphous crystal form of the antiallergic cetirizine dihydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Rao, Uppala Venkata Bhaskara; Reddy, Konda Srinivasa
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004266787	A1	20041230	US 2004-809193	20040325
IN 2003MA00253	A	20050304	IN 2003-MA253	20030325
PRIORITY APPLN. INFO.:			IN 2003-MA253 A	20030325

AB An amorphous form of the antiallergic compound cetirizine dihydrochloride, prepared by the base-promoted hydrolysis of the corresponding amide of certizine, extraction, followed by HCl salification, is prepared as are pharmaceutical compns. utilizing this crystalline form.
IT 83881-52-1P, Cetirizine dihydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of an amorphous crystal form of the antiallergic cetirizine dihydrochloride)
RN 83881-52-1 CAPLUS
CN Acetic acid, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:493694 CAPLUS
DOCUMENT NUMBER: 141:54360
TITLE: Polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation
INVENTOR(S): Reddy, Manne Satyanarayana; Srinivasan, Thirumalai Rajan; Uppala, Venkata Bhaskara Rao; Vaddadi, Pattabhi Ramayya; Joga, Rajender
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050647	A2	20040617	WO 2003-US38494	20031204
WO 2004050647	A3	20040902		
WO 2004050647	A8	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2002MA00908	A	20050304	IN 2002-MA908	20021204
CA 2488114	A1	20040617	CA 2003-2488114	20031204
AU 2003297640	A1	20040623	AU 2003-297640	20031204
US 2004186112	A1	20040923	US 2003-729856	20031204
CN 1692105	A	20051102	CN 2003-80100543	20031204
PRIORITY APPLN. INFO.:			IN 2002-MA908 A	20021204
			WO 2003-US38494 W	20031204

AB Crystalline polymorphic forms of the levorotatory and dextrorotatory cetirizine dihydrochloride salts are prepared by dissolving the salts in an a ketone-containing solvent (e.g., aqueous acetone), cooling the solution, and
collecting the crystalline precipitate
IT 130018-87-0P 163837-48-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation)
RN 130018-87-0 CAPLUS
CN Acetic acid, 2-[2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl

RN 163837-48-7 CAPLUS
CN Acetic acid, [2-[4-[(S)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:991494 CAPLUS
DOCUMENT NUMBER: 140:42205
TITLE: Preparation of crystalline [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride)
INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Shankar, Ranga Ravi; Vardhan, Sunkara Vishnu
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104211	A2	20031218	WO 2003-US17672	20030604
WO 2003104211	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2002MA00425	A	20050304	IN 2002-MA425	20020605
AU 2003237394	A1	20031222	AU 2003-237394	20030604
PRIORITY APPLN. INFO.:			IN 2002-MA425 A	20020605
			WO 2003-US17672 W	20030604

OTHER SOURCE(S): CASREACT 140:42205
AB A crystalline form of cetirizine dihydrochloride (I), prepared by the salification of cetirizine with isopropanolic hydrogen chloride, having a defined X-ray diffraction pattern is presented, and pharmaceutical compns. containing I are presented.
IT 83881-52-1P, Cetirizine dihydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
RN 83881-52-1 CAPLUS
CN Acetic acid, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:918224 CAPLUS
DOCUMENT NUMBER: 137:389216
TITLE: Cetirizine and sympathomimetic combinations for the treatment of nasal obstruction
INVENTOR(S): Okudaira, Ichiro; Ichihara, Takashi; Nakagami, Joji; Aikawa, Katsuyoshi; Nakagawa, Yasuo
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002348240	A	20021204	JP 2001-156277	20010525
PRIORITY APPLN. INFO.:			JP 2001-156277	20010525

AB This invention relates to compns. for the treatment of nasal obstruction from rhinitis caused by common cold, allergy, etc. The compns. comprise (1) cetirizine or salts thereof and (2) ≥ 1 substance selected from the group consisting of phenylpropanolamine, methylephedrine, phenylephrine, methoxyphenamine, and salts thereof. For example, a tablet (200 mg each) contained cetirizine hydrochloride 5, phenylpropanolamine hydrochloride 75, anhydrous caffeine 75, lactose 140, crystalline cellulose 140, and Mg stearate 15 parts.

IT 83881-52-1, Cetirizine hydrochloride
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cetirizine and sympathomimetic combinations for treatment of nasal obstruction)

RN 83881-52-1 CAPLUS
CN Acetic acid, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl